ImmunityBio announces proposed public offering of common stock
| IBRX Stock | USD 3.47 0.31 9.81% |
Slightly above 55% of Immunitybio's investors are presently thinking to get in. The analysis of overall sentiment of trading Immunitybio stock suggests that some investors are interested at this time. Immunitybio's investing sentiment can be driven by a variety of factors including economic data, Immunitybio's earnings reports, geopolitical events, and overall market trends.
Immunitybio |
ImmunityBio announces public offering of common stock to fund commercialization and research for cancer treatments.
Read at seekingalpha.com
 |
Immunitybio Fundamental Analysis
We analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Immunitybio is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Immunitybio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunitybio stock to make a market-neutral strategy. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics with similar companies.
Peers
Immunitybio Related Equities
| PPCB | Propanc Biopharma | 108.33 | ||||
| PDSB | PDS Biotechnology | 9.21 | ||||
| ELEV | Elevation Oncology | 8.06 | ||||
| MCRB | Seres Therapeutics | 6.17 | ||||
| MDGL | Madrigal Pharmaceuticals | 3.67 | ||||
| ARDX | Ardelyx | 2.05 | ||||
| VKTX | Viking Therapeutics | 0.78 | ||||
| PLX | Protalix Biotherapeutics | 0.42 | ||||
| TGTX | TG Therapeutics | 0.03 | ||||
| KRYS | Krystal Biotech | 0.15 | ||||
| LXRX | Lexicon Pharmaceuticals | 1.20 | ||||
| CVAC | CureVac NV | 1.29 | ||||
| VIR | Vir Biotechnology | 5.41 | ||||
| XFOR | X4 Pharmaceuticals | 10.81 | ||||
| BLRX | BioLineRx | 15.40 |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.